Form 4: Cidara Therapeutics CEO Acquires Stock Options
SEC Form 4 Filing
Cidara Therapeutics' CEO, Jeffrey Stein, was granted stock options on September 30, 2024.
Summary
- Jeffrey Stein, the President & CEO of Cidara Therapeutics, Inc., acquired 560,888 employee stock options on September 30, 2024.
- The exercise price of these options is $10.75.
- The options vest in 36 equal monthly installments starting from September 30, 2024, and expire on September 29, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance, but it's not overwhelmingly positive.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
- The size of the grant and the vesting schedule are typical for a CEO of a company of Cidara's size and stage of development.
- Comparable companies such as BioCryst Pharmaceuticals and Nabriva Therapeutics also utilize stock options as part of their executive compensation strategy.
Stakeholder Impact
- The stock option grant could potentially increase shareholder value if the CEO successfully leads the company to growth and profitability.
- Employees may view the grant positively as it aligns the CEO's interests with the company's success.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of earliest transaction (grant of stock options) and Vesting Commencement Date |
| 09/29/2034 | Expiration date of the stock options |
| 10/02/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.